Close

pCDCAR1 GPC3 h(28ζ) (CAR-LC047)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-GPC3 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human GPC3. The T cells are genetically modified through transduction with a retroviral vector expressing scFv of anti-GPC3 antibody linked to CD28 and CD3ζ signaling domain. And the vector product was designed for the treatment of hepatocellular carcinoma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • Glypican-3 (GPC3)
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Hepatocellular Carcinoma
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Retroviral
  • Receptor Construction
  • scFv-CD28-CD3ζ
  • Discription of Signaling Cassetes
  • CD28
    CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • GC33
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • glypican 3
  • Synonyms
  • GPC3;GPC3; glypican 3; SGB; DGSX; MXR7; SDYS; SGBS; OCI-5; SGBS1; GTR2-2;

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FM

Fig.1 Flow analysis of GPC3-specific CARs expression on human T cells transduced with lentiviral particles.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.1 Flow analysis of GPC3-specific CARs expression on human T cells transduced with lentiviral particles.

GPC3-specific CARs expression on human T cells transduced with lentiviral particles were analyzed using flow cytometry by detection of GFP autofluorescence.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data FuncS

Fig.2 Antigen-specific reproliferation analysis of αGPC3-28BBZ CAR-T.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.2 Antigen-specific reproliferation analysis of αGPC3-28BBZ CAR-T.

In vitro expansion of T cells with stimulation of αCD3/αCD28-coated magnetic beads on day 0 and transduction with the indicated CARs on day 1. Cultured 2 weeks. On day 18, T cells were restimulated by aK562-64/86 with coexpression of the extracellular domain of CD64 and CD86, in the presence of OKT3 (100 ng/mL) and recombinant human IL2 (300 U/mL). D, on day 18, the general or antigen-specific reproliferation of αGPC3-28BBZ ransduced T cells were quantified.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data FuncS

Fig.3 IL2 produced by GPC3-targeted CAR T cells cocultured with various HCC cell lines.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.3 IL2 produced by GPC3-targeted CAR T cells cocultured with various HCC cell lines.

IL2 were secreted by the indicated genetically modified T cells cocultured with various HCC cell lines for 24 hours.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data FuncS

Fig.4 IFNγ produced by GPC3-targeted CAR T cells cocultured with various HCC cell lines.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.4 IFNγ produced by GPC3-targeted CAR T cells cocultured with various HCC cell lines.

IFNγ were secreted by the indicated genetically modified T cells cocultured with various HCC cell lines for 24 hours.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data FuncS

Fig.5 Correlation between the IFNγ secretion from GPC3-targeted T cells and the MFI of GPC3 expression on the five HCC cell lines.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.5 Correlation between the IFNγ secretion from GPC3-targeted T cells and the MFI of GPC3 expression on the five HCC cell lines.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data Cyt

Fig.6 In vitro cytotoxic activities of GPC3-targeted CAR T cells with hepg2 cell.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.6 In vitro cytotoxic activities of GPC3-targeted CAR T cells with hepg2 cell.

Primary human T cells transduced with the indicated lentiviral vectors were coincubated with the five HCC cell lines at the varying effector: target ratios for 18 hours, respectively.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data Cyt

Fig.7 In vitro cytotoxic activities of GPC3-targeted CAR T cells with huh-7 cell.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.7 In vitro cytotoxic activities of GPC3-targeted CAR T cells with huh-7 cell.

Primary human T cells transduced with the indicated lentiviral vectors were coincubated with the five HCC cell lines at the varying effector: target ratios for 18 hours, respectively.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data Cyt

Fig.8 In vitro cytotoxic activities of GPC3-targeted CAR T cells with hep3B CELL.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.8 In vitro cytotoxic activities of GPC3-targeted CAR T cells with hep3B CELL.

Primary human T cells transduced with the indicated lentiviral vectors were coincubated with the five HCC cell lines at the varying effector: target ratios for 18 hours, respectively.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data Cyt

Fig.9 In vitro cytotoxic activities of GPC3-targeted CAR T cells with plc/prf/5 CELL.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.9 In vitro cytotoxic activities of GPC3-targeted CAR T cells with plc/prf/5 CELL.

Primary human T cells transduced with the indicated lentiviral vectors were coincubated with the five HCC cell lines at the varying effector: target ratios for 18 hours, respectively.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data Cyt

Fig.10 In vitro cytotoxic activities of GPC3-targeted CAR T cells with SK-HEP-1 CELL.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.10 In vitro cytotoxic activities of GPC3-targeted CAR T cells with SK-HEP-1 CELL.

Primary human T cells transduced with the indicated lentiviral vectors were coincubated with the five HCC cell lines at the varying effector: target ratios for 18 hours, respectively.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data Cyt

Fig.11 Cytotoxicity of αGPC3-28BBZ CAR T cells on Huh-7 cells in the absence or presence of mammalian cell-expressed GPC3ΔGPI and GPC3N.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.11 Cytotoxicity of αGPC3-28BBZ CAR T cells on Huh-7 cells in the absence or presence of mammalian cell-expressed GPC3ΔGPI and GPC3N.

E.coli-expressed GST-fused GC33-binding peptide or BSA at the effector:target ratio of 3:1 for 18 hours.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data FuncS

Fig.12 In vivo antitumor activities of αGPC3-28BBZ CAR T cells on established subcutaneous Huh-7 HCC tumor xenografts.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.12 In vivo antitumor activities of αGPC3-28BBZ CAR T cells on established subcutaneous Huh-7 HCC tumor xenografts.

Growth curve of Huh-7 xenografts treated with the indicated T cells or saline.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data FuncS

Fig.13 In vivo antitumor activities of αGPC3-28BBZ CAR T cells on established subcutaneous PLC/PRF/5 HCC tumor xenografts.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.13 In vivo antitumor activities of αGPC3-28BBZ CAR T cells on established subcutaneous PLC/PRF/5 HCC tumor xenografts.

Growth curve of PLC/PRF/5 xenografts treated with the indicated T cells or saline.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data FuncS

Fig.14 In vivo antitumor activities of αGPC3-28BBZ CAR T cells on established subcutaneous Huh-7 HCC tumor xenografts.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.14 In vivo antitumor activities of αGPC3-28BBZ CAR T cells on established subcutaneous Huh-7 HCC tumor xenografts.

The quantities of circulating human CD4+ and CD8+ T cells from mice bearing Huh-7 xenografts treated with the indicated genetically modified T cells.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data FuncS

Fig.15 In vivo antitumor activities of αGPC3-28BBZ CAR T cells on established subcutaneous PLC/PRF/5 HCC tumor xenografts.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.15 In vivo antitumor activities of αGPC3-28BBZ CAR T cells on established subcutaneous PLC/PRF/5 HCC tumor xenografts.

The quantities of circulating human CD4+ and CD8+ T cells from mice bearing PLC/PRF/5 treated with the indicated genetically modified T cells.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data FuncS

Fig.16 αGPC3-28BBZ CAR T cells potently suppressed the established orthotopic Huh-7 xenografts in vivo.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.16 αGPC3-28BBZ CAR T cells potently suppressed the established orthotopic Huh-7 xenografts in vivo.

The growth of tumors treated with αGPC3-28BBZ CAR T cells was potently suppressed when compared with the control groups.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data FuncS

Fig.17 αGPC3-28BBZ CAR T cells potently suppressed the established orthotopic Huh-7 xenografts in vivo.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.17 αGPC3-28BBZ CAR T cells potently suppressed the established orthotopic Huh-7 xenografts in vivo.

The quantitative analysis of human CD4+ and CD8+ T cells by TruCount tubes.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data FuncS

Fig.18 αGPC3-28BBZ CAR T cells potently suppressed the established orthotopic Huh-7 xenografts in vivo.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.18 αGPC3-28BBZ CAR T cells potently suppressed the established orthotopic Huh-7 xenografts in vivo.

The quantitative analysis of GFP-positive peripheral blood cells.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data FuncS

Fig.19 αGPC3-28BBZ CAR T cells potently suppressed the established orthotopic Huh-7 xenografts in vivo.

CAR Construction : GC33 scfv-CD3ζ; GC33 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.19 αGPC3-28BBZ CAR T cells potently suppressed the established orthotopic Huh-7 xenografts in vivo.

The overall survival of mice treated with the indicated T cells or saline.

Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., ... & Li, Z. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular CarcinomaGPC3-Targeted CAR T Cells for HCC Treatment. Clinical Cancer Research, 20(24), 6418-6428.

Complete CAR data Cyt

Fig.20 Cytotoxicity and cytokine production of different CARTs.

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.20 Cytotoxicity and cytokine production of different CARTs.

The fold of increase over mock-T cells were presented. Each data was from the combined media of triplicate wells. Two Luminex testing repeats were conducted.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data Cyt

Fig.21 Comparison of the cytotoxicity of CARs with and without mCherry tag.

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.21 Comparison of the cytotoxicity of CARs with and without mCherry tag.

Triplicate wells were used at each time point. The experiment was repeated 3 times with similar observation.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data FuncS

Fig.22 GC33 CARTs do not kill normal primary human cells.

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.22 GC33 CARTs do not kill normal primary human cells.

Primary human cells were co-cultured with CARTs for 24hrs and the media were used for LDH assay. HepG2 cells were used as positive control.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data FuncS

Fig.23 In vivo antitumor activities of αGPC3 CAR T cells.

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.23 In vivo antitumor activities of αGPC3 CAR T cells.

Bioluminescent imaging (BLI) of the IP tumors. All images at different time points and from different groups were adjusted to the same scale.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data FuncS

Fig.24 Tumor BLI kinetics of αGPC3 CAR T cells antitumor activities in vivo.

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.24 Tumor BLI kinetics of αGPC3 CAR T cells antitumor activities in vivo.

Tumor BLI kinetics of each individual mouse, 5 mice in each treated group.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data FuncS

Fig.25 Detection of hCD45 T cells and CAR+ T cells in the blood.

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.25 Detection of hCD45 T cells and CAR+ T cells in the blood.

Statistical analysis was done with SAS System GLM procedure.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data FuncS

Fig.26 The change of hCD45+T cells in the blood from DI 2 to DI 6 after ACT.

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.26 The change of hCD45+T cells in the blood from DI 2 to DI 6 after ACT.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data FuncS

Fig.27 Tumor BLI kinetics after CART treatment.

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.27 Tumor BLI kinetics after CART treatment.

Each line represented an individual tumor.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data FuncS

Fig.28 Representative IHC staining of tumor infiltraing CD8T cells at indicated time points after ACT.

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.28 Representative IHC staining of tumor infiltraing CD8T cells at indicated time points after ACT.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data FuncS

Fig.29 Summary of the tumor infiltrating CART numbers of 5 mice from 3 time points (DI 3, D18 and D2l).

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.29 Summary of the tumor infiltrating CART numbers of 5 mice from 3 time points (DI 3, D18 and D2l).

The number was normalized by dividing the total CART number in the tumor by the corresponding tumor mass BLI. The experiment was repeated twice and similar data was observed.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data FuncS

Fig.30 The gating strategy for enumerating the tumor infiltrating CARTs.

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.30 The gating strategy for enumerating the tumor infiltrating CARTs.

The viable cells from the single tumor cell suspension were counted by Trypan blue. The CART number in the tumor was calculated by the total viable cells in the tumor x% of hCD45 x %of CAR+.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data FuncS

Fig.31 The exhaustion and apoptosis of tumor-infiltrating CARTs at D21 after ACT.

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.31 The exhaustion and apoptosis of tumor-infiltrating CARTs at D21 after ACT.

The tumor infiltrating CARTs from the single cell suspensions were stained and gated.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data FuncS

Fig.32 Summary of the exhaustion and apoptosis of tumor infiltrating CARTs.

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.32 Summary of the exhaustion and apoptosis of tumor infiltrating CARTs.

The % of PD1 + and LAG+ of CARTs, and the MFI of Annexin V on CARTs were summarized from 3 mice.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data FuncS

Fig.33 The apoptosis staining of CAR- and CAR+T cells after HepG2 stimulation.

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.33 The apoptosis staining of CAR- and CAR+T cells after HepG2 stimulation.

The numbers in the figure indicate the MFI of Anne×in-VThe dynamic changes of apoptosis was also summarized.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data FuncS

Fig.34 The %and MFI of exhaustion markers, and the %of PD1 and LAG3 double positive cells among the CARTs after HepG2 stimulation were presented.

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.34 The %and MFI of exhaustion markers, and the %of PD1 and LAG3 double positive cells among the CARTs after HepG2 stimulation were presented.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data FuncS

Fig.35 The %of PD1 and LAG3 double positive cells among the CARTs after HepG2 stimulation were presented.

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.35 The %of PD1 and LAG3 double positive cells among the CARTs after HepG2 stimulation were presented.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data FuncS

Fig.36 The % of central memory (Tern) and naive-like cells (Tnaive) cells in the CAR+ cells after HepG2 co-culture were shown.

CAR Construction : GC33 scfv-CD28-CD3ζ; GC33 scfv-41BB-CD3ζ Latest CAR Construction

Fig.36 The % of central memory (Tern) and naive-like cells (Tnaive) cells in the CAR+ cells after HepG2 co-culture were shown.

Each data point represents mean+/-SD of triplicate wells. The experiments were repeated 3 times with similar observation.

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., ... & He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology, 76(2), 330-344.

Complete CAR data FuncS

Fig.37 GPC-3.CAR/sIL-15 Vδ1 T cells exert robust in vitro antitumor activity against GPC-3-expressing tumor cell lines

CAR Construction : GC33 scfv-41BB-CD3ζ-IL15 Latest CAR Construction

Fig.37 GPC-3.CAR/sIL-15 Vδ1 T cells exert robust in vitro antitumor activity against GPC-3-expressing tumor cell lines

GPC-3.CAR Vδ1 were cocultured with RFluc-expressing GPC-3+ HepG2 and PLC/PRF/5 (PLC) liver cancer cell lines (top panels) or GPC-3- SKMEL5 and HCT116 melanoma and colon cancer cell lines (bottom panels) across listed E:T ratios for ~18-hour.

Makkouk, A., Yang, X. C., Barca, T., Lucas, A., Turkoz, M., Wong, J. T., ... & Herrman, M. (2021). Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Journal for immunotherapy of cancer, 9(12).

Complete CAR data Cyt

Fig.38 Cytotoxic potential of GPC-3.CAR/sIL-15 Vδ1 T cells against HepG2 and PLC cells at a fixed 1:1 ratio was assessed in the presence of soluble GPC-3 (0.3μg/mL-20 μg/mL) in an 18 hours cytotoxicity assay.

CAR Construction : GC33 scfv-41BB-CD3ζ-IL15 Latest CAR Construction

Fig.38 Cytotoxic potential of GPC-3.CAR/sIL-15 Vδ1 T cells against HepG2 and PLC cells at a fixed 1:1 ratio was assessed in the presence of soluble GPC-3 (0.3μg/mL-20 μg/mL) in an 18 hours cytotoxicity assay.

Per cent inhibition was calculated relative to the T cell alone control.

Makkouk, A., Yang, X. C., Barca, T., Lucas, A., Turkoz, M., Wong, J. T., ... & Herrman, M. (2021). Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Journal for immunotherapy of cancer, 9(12).

Complete CAR data FuncS

Fig.39 Cytokine production by GPC-3.CAR/sIL-15 and GPC-3.CAR Vδ1 T cell effectors after a 24hours co-culture with HepG2 cells at 2:1 E:T ratio.

CAR Construction : GC33 scfv-41BB-CD3ζ-IL15 Latest CAR Construction

Fig.39 Cytokine production by GPC-3.CAR/sIL-15 and GPC-3.CAR Vδ1 T cell effectors after a 24hours co-culture with HepG2 cells at 2:1 E:T ratio.

Makkouk, A., Yang, X. C., Barca, T., Lucas, A., Turkoz, M., Wong, J. T., ... & Herrman, M. (2021). Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Journal for immunotherapy of cancer, 9(12).

Complete CAR data FuncS

Fig.40 Cytokine production by GPC-3.CAR/sIL-15 and GPC-3.CAR Vδ1 T cell effectors after a 24hours co-culture with PLC cells at 2:1 E:T ratio.

CAR Construction : GC33 scfv-41BB-CD3ζ-IL15 Latest CAR Construction

Fig.40 Cytokine production by GPC-3.CAR/sIL-15 and GPC-3.CAR Vδ1 T cell effectors after a 24hours co-culture with PLC cells at 2:1 E:T ratio.

Makkouk, A., Yang, X. C., Barca, T., Lucas, A., Turkoz, M., Wong, J. T., ... & Herrman, M. (2021). Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Journal for immunotherapy of cancer, 9(12).

Complete CAR data Cyt

Fig.41 Cytotoxic potential of GPC-3.CAR and GPC-3.CAR/sIL-15 Vδ1 T cells against PLC cells in a long-term cytotoxicity assay (2.5:1 E:T ratio).

CAR Construction : GC33 scfv-41BB-CD3ζ-IL15 Latest CAR Construction

Fig.41 Cytotoxic potential of GPC-3.CAR and GPC-3.CAR/sIL-15 Vδ1 T cells against PLC cells in a long-term cytotoxicity assay (2.5:1 E:T ratio).

Makkouk, A., Yang, X. C., Barca, T., Lucas, A., Turkoz, M., Wong, J. T., ... & Herrman, M. (2021). Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Journal for immunotherapy of cancer, 9(12).

Complete CAR data Cyt

Fig.42 Cytotoxic potential of GPC-3 CAR Vδ1 T cells against PLC spheroids.

CAR Construction : GC33 scfv-41BB-CD3ζ-IL15 Latest CAR Construction

Fig.42 Cytotoxic potential of GPC-3 CAR Vδ1 T cells against PLC spheroids.

CAR and GPC-3.CAR/sIL-15 Vδ1 T cells against PLC spheroids in a long-term cytotoxicity assay (2:1 E:T ratio).

Makkouk, A., Yang, X. C., Barca, T., Lucas, A., Turkoz, M., Wong, J. T., ... & Herrman, M. (2021). Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Journal for immunotherapy of cancer, 9(12).

Complete CAR data Cyt

Fig.43 Proliferation monitoring analysis of GPC-3 CAR Vδ1 T cells in cytotoxicity assay.

CAR Construction : GC33 scfv-41BB-CD3ζ-IL15 Latest CAR Construction

Fig.43 Proliferation monitoring analysis of GPC-3 CAR Vδ1 T cells in cytotoxicity assay.

On days 1, 3, 5, and 7 from the long-term cytotoxicity assay in fig.42, replicate wells were sacrificed for Vδ1 cell quantification (top) and proliferation monitoring (bottom) by flow cytometry.

Makkouk, A., Yang, X. C., Barca, T., Lucas, A., Turkoz, M., Wong, J. T., ... & Herrman, M. (2021). Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Journal for immunotherapy of cancer, 9(12).

Complete CAR data FuncS

Fig.44 Proliferative potential of GPC-3.CAR and GPC-3.CAR/sIL-15 Vδ1 T cells in tumor, bone marrow, spleen, blood, and lungs for ex vivo analysis.

CAR Construction : GC33 scfv-41BB-CD3ζ-IL15 Latest CAR Construction

Fig.44 Proliferative potential of GPC-3.CAR and GPC-3.CAR/sIL-15 Vδ1 T cells in tumor, bone marrow, spleen, blood, and lungs for ex vivo analysis.

(A) Schematic for ex vivo analysis of Vδ1 T cells in HepG2 tumor-bearing NSG mice. (B) Proliferative potential of GPC-3.

Makkouk, A., Yang, X. C., Barca, T., Lucas, A., Turkoz, M., Wong, J. T., ... & Herrman, M. (2021). Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Journal for immunotherapy of cancer, 9(12).

Complete CAR data FuncS

Fig.45 Differentiation potential of GPC-3.CAR and GPC-3.CAR/sIL-15 Vδ1 T cells in the spleen and tumor for ex vivo analysis.

CAR Construction : GC33 scfv-41BB-CD3ζ-IL15 Latest CAR Construction

Fig.45 Differentiation potential of GPC-3.CAR and GPC-3.CAR/sIL-15 Vδ1 T cells in the spleen and tumor for ex vivo analysis.

Makkouk, A., Yang, X. C., Barca, T., Lucas, A., Turkoz, M., Wong, J. T., ... & Herrman, M. (2021). Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Journal for immunotherapy of cancer, 9(12).

Complete CAR data FuncS

Fig.46 In vivo efficacy of a single dose of car Vδ1 T cells in HepG2 tumor-bearing NSG mice.

CAR Construction : GC33 scfv-41BB-CD3ζ-IL15 Latest CAR Construction

Fig.46 In vivo efficacy of a single dose of car Vδ1 T cells in HepG2 tumor-bearing NSG mice.

(D) Study schematic. (E) Tumor growth kinetics (left) and tumor volumes on day 38 (right).

Makkouk, A., Yang, X. C., Barca, T., Lucas, A., Turkoz, M., Wong, J. T., ... & Herrman, M. (2021). Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Journal for immunotherapy of cancer, 9(12).

Complete CAR data FuncS

Fig.47 In vivo efficacy of a single dose of GPC-3.CAR and GPC-3.CAR/sIL-15 Vδ1 T cells in combination with interleukin-2 in HepG2 tumor-bearing NSG mice.

CAR Construction : GC33 scfv-41BB-CD3ζ-IL15 Latest CAR Construction

Fig.47 In vivo efficacy of a single dose of GPC-3.CAR and GPC-3.CAR/sIL-15 Vδ1 T cells in combination with interleukin-2 in HepG2 tumor-bearing NSG mice.

(F) Study schematic. (G) Tumor growth kinetics (left) and tumor volumes on day 35 (right).

Makkouk, A., Yang, X. C., Barca, T., Lucas, A., Turkoz, M., Wong, J. T., ... & Herrman, M. (2021). Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Journal for immunotherapy of cancer, 9(12).

Complete CAR data FuncS

Fig.48 GPC-3.CAR/sIL-15 Vδ1 T cells do not induce toxicity or GvHD as determined by histopathological analysis.

CAR Construction : GC33 scfv-41BB-CD3ζ-IL15 Latest CAR Construction

Fig.48 GPC-3.CAR/sIL-15 Vδ1 T cells do not induce toxicity or GvHD as determined by histopathological analysis.

On day 45 post-treatment, mice treated with GPC-3.CAR/sIL-15 Vδ1 T cells and from remaining control mice were euthanized and spleens, lungs, livers and skin were collected from each animal for histopathology analysis and for assessing infiltration of human CD3+ cells by immunohistochemistry.

Makkouk, A., Yang, X. C., Barca, T., Lucas, A., Turkoz, M., Wong, J. T., ... & Herrman, M. (2021). Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Journal for immunotherapy of cancer, 9(12).

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-GPC3 (GC33) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-LC047). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.